As of 2026-03-31, the Relative Valuation of Heron Therapeutics Inc (HRTX) is (1.79) USD. This relative valuation is based on P/E multiples. With the latest stock price at 0.75 USD, the upside of Heron Therapeutics Inc based on Relative Valuation is -340.5%.
The range of the Relative Valuation is (1.39) - (2.08) USD.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| Trailing P/E multiples | 13.0x - 19.4x | 17.6x |
| Forward P/E multiples | 11.7x - 19.4x | 15.9x |
| Fair Price | (1.39) - (2.08) | (1.79) |
| Upside | -286.1% - -378.9% | -340.5% |
| Date | P/E |
| 2026-03-27 | -7.32 |
| 2026-03-26 | -7.70 |
| 2026-03-25 | -7.43 |
| 2026-03-24 | -7.14 |
| 2026-03-23 | -7.47 |
| 2026-03-20 | -7.27 |
| 2026-03-19 | -7.63 |
| 2026-03-18 | -7.84 |
| 2026-03-17 | -8.09 |
| 2026-03-16 | -8.38 |
| 2026-03-13 | -8.23 |
| 2026-03-12 | -8.66 |
| 2026-03-11 | -9.06 |
| 2026-03-10 | -9.23 |
| 2026-03-09 | -9.30 |
| 2026-03-06 | -9.02 |
| 2026-03-05 | -9.52 |
| 2026-03-04 | -10.55 |
| 2026-03-03 | -10.74 |
| 2026-03-02 | -11.20 |
| 2026-02-27 | -11.11 |
| 2026-02-26 | -11.20 |
| 2026-02-25 | -10.08 |
| 2026-02-24 | -10.18 |
| 2026-02-23 | -11.11 |
| 2026-02-20 | -11.02 |
| 2026-02-19 | -11.11 |
| 2026-02-18 | -11.30 |
| 2026-02-17 | -11.11 |
| 2026-02-13 | -10.74 |
| 2026-02-12 | -10.74 |
| 2026-02-11 | -10.92 |
| 2026-02-10 | -11.86 |
| 2026-02-09 | -11.95 |
| 2026-02-06 | -11.76 |
| 2026-02-05 | -11.30 |
| 2026-02-04 | -12.32 |
| 2026-02-03 | -12.79 |
| 2026-02-02 | -12.88 |
| 2026-01-30 | -12.32 |
| 2026-01-29 | -12.51 |
| 2026-01-28 | -12.42 |
| 2026-01-27 | -13.07 |
| 2026-01-26 | -13.44 |
| 2026-01-23 | -13.26 |
| 2026-01-22 | -13.54 |
| 2026-01-21 | -13.63 |
| 2026-01-20 | -13.26 |
| 2026-01-16 | -13.91 |
| 2026-01-15 | -13.91 |